Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Rare sugars curb appetite and mimic diabetes drugs in mice

Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in mice. D-allose also reduced food intake through a unique, GLP-1-independent pathway.

1 Apr 2025

UVA Health experts highlight a growing array of treatment options for type 2 diabetes

Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year, UVA Health diabetes experts note in a new paper highlighting a growing array of treatment options.

1 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

31 Mar 2025

Why sucralose could make you hungrier instead of helping you lose weight

Sucralose increases hypothalamic activity linked to hunger more than sugar or water, especially in women and people with obesity.

30 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

Dopamine neurons play a central role in sustaining hedonic eating

A previously overlooked dopamine-producing brain circuit drives hedonic eating, or eating for pleasure, according to a new study in mice.

27 Mar 2025

Older Americans support insurance coverage for obesity medications

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.

27 Mar 2025

Unveiling leptin signaling in the DMH for metabolic effects

Scientists at Pennington Biomedical Research Center have gained greater clarity in the brain regions and neurons that control metabolism, body temperature and energy use.

27 Mar 2025

Common sugar substitute increases activity in the brain's hypothalamus

Compared to sugar, consuming sucralose-a widely used sugar substitute-increases activity in the hypothalamus, a brain region that regulates appetite and body weight, according to a new USC study.

26 Mar 2025

Flavonoids help regulate gut hormones and show promise in managing type 2 diabetes

Flavonoids show promise in treating type 2 diabetes mellitus by targeting the enteroendocrine system and regulating key gut hormones. They enhance insulin sensitivity, reduce oxidative stress, and influence appetite, glucose uptake, and hormone secretion.

26 Mar 2025

Discovery provides crucial molecular targets for future obesity treatments

The pleasure we get from eating junk food - the dopamine rush from crunching down on salty, greasy French fries and a luscious burger - is often blamed as the cause of overeating and rising obesity rates in our society.

26 Mar 2025

US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies

Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.

25 Mar 2025

Healthcare groups urge FDA to act on compounding regulations after GLP-1 medicine shortages

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across the healthcare continuum, urging the agency to enforce federal regulations around compounding following the recent resolution of GLP-1 medicine shortages.

22 Mar 2025

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired glucose homeostasis.

20 Mar 2025

Early use of anti-obesity medication doubles weight loss

Adding an anti-obesity medication just one month after behavioral therapy begins-rather than waiting the currently recommended six months-can more than double weight loss for patients who struggle initially with lifestyle changes alone, according to new research published in Nature Medicine from a team at the Perelman School of Medicine at the University of Pennsylvania.

18 Mar 2025

Semaglutide

Overview

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Latest Semaglutide News and Research

Rare sugars curb appetite and mimic diabetes drugs in mice

UVA Health experts highlight a growing array of treatment options for type 2 diabetes

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Why sucralose could make you hungrier instead of helping you lose weight

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Dopamine neurons play a central role in sustaining hedonic eating

Older Americans support insurance coverage for obesity medications

Unveiling leptin signaling in the DMH for metabolic effects

Common sugar substitute increases activity in the brain's hypothalamus

Flavonoids help regulate gut hormones and show promise in managing type 2 diabetes

Discovery provides crucial molecular targets for future obesity treatments

US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies

Healthcare groups urge FDA to act on compounding regulations after GLP-1 medicine shortages

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Early use of anti-obesity medication doubles weight loss

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

Keto controversy? Experts say it’s here to stay

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

New insights into screening and treatment for diabetic retinal disease

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Semaglutide

Overview

Latest Semaglutide News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in